Hematologic Malignancy
Chronic Leukemia
CI-CAN-00000764Explore in graph →
Hematologic411 active trials10 approved drugs59 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000764Explore in graph →
Clinical trials
1,705 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (302)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04008706 | Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients(ASSURE) | completed | Phase 3 | 552 | AstraZenecaINDUSTRY | 17 | Sep 1, 2026 | clinicaltrials |
| NCT03480360 | Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression | completed | Phase 3 | 21 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Jul 17, 2026 |
| NCT01231412 | Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant | completed | Phase 3 | 174 | Fred Hutchinson Cancer CenterOTHER | 3 | Apr 30, 2026 | clinicaltrials |
| NCT00931645 | Autologous Stem Cell Transplantation in Chronic Lymphocytic Leukemia(Auto-LLC 2001) | completed | Phase 3 | 241 | University Hospital, CaenOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT02242942 | Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia | completed | Phase 3 | 445 | Hoffmann-La RocheINDUSTRY | 21 | Nov 6, 2025 | clinicaltrials |
| NCT03734016 | A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia(ALPINE) | completed | Phase 3 | 652 | BeiGeneINDUSTRY | 15 | Mar 30, 2025 | clinicaltrials |
| NCT04178798 | Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic Leukemia | completed | Phase 3 | 22 | PETHEMA FoundationOTHER | 1 | Mar 17, 2025 | clinicaltrials |
| NCT00769522 | FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia | completed | Phase 3 | 564 | German CLL Study GroupOTHER | 1 | Dec 31, 2024 | clinicaltrials |
| NCT02863718 | Ibrutinib in Previously Untreated Binet Stage A Chronic Lymphocytic Leukemia With Risk of Disease Progression(CLL12) | completed | Phase 3 | 515 | German CLL Study GroupOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT01724346 | Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 3 | 269 | Pharmacyclics LLC.INDUSTRY | 16 | Sep 19, 2024 | clinicaltrials |
| NCT03306264 | Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML | completed | Phase 3 | 227 | Astex Pharmaceuticals, Inc.INDUSTRY | 10 | Aug 27, 2024 | clinicaltrials |
| NCT00991211 | Bendamustine Plus Rituximab Versus CHOP Plus Rituximab | completed | Phase 3 | 549 | University of GiessenOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT02005471 | A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)(MURANO) | completed | Phase 3 | 389 | Hoffmann-La RocheINDUSTRY | 20 | Oct 17, 2023 | clinicaltrials |
| NCT01428635 | Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy | completed | Phase 2 / Phase 3 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT02004522 | A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO) | completed | Phase 3 | 319 | SecuraBioINDUSTRY | 11 | Sep 21, 2023 | clinicaltrials |
| NCT02049515 | A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07 | completed | Phase 3 | 99 | SecuraBioINDUSTRY | 11 | Sep 21, 2023 | clinicaltrials |
| NCT01951885 | Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention | completed | Phase 3 | 101 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT02756611 | A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)(VENICE I) | completed | Phase 3 | 258 | AbbVieINDUSTRY | 21 | Apr 10, 2023 | clinicaltrials |
| NCT02301156 | Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)(GENUINE) | completed | Phase 3 | 126 | TG Therapeutics, Inc.INDUSTRY | 2 | May 20, 2022 | clinicaltrials |
| NCT00450450 | Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases | completed | Phase 3 | 27 | Children's Oncology GroupNETWORK | 1 | Apr 28, 2022 | clinicaltrials |
| NCT01556776 | A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy | completed | Phase 3 | 89 | German CLL Study GroupOTHER | 1 | Jan 5, 2022 | clinicaltrials |
| NCT01241500 | Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts(ONTIME) | completed | Phase 3 | 299 | Traws Pharma, Inc.INDUSTRY | 6 | Jun 30, 2020 | clinicaltrials |
| NCT01928537 | Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine | completed | Phase 3 | 67 | Traws Pharma, Inc.INDUSTRY | 8 | Jun 30, 2020 | clinicaltrials |
| NCT01829711 | Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia | completed | Phase 3 | 80 | MedImmune LLCINDUSTRY | 14 | Apr 8, 2020 | clinicaltrials |
| NCT01569295 | Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )(Tugela) | completed | Phase 3 | 416 | Gilead SciencesINDUSTRY | 18 | Mar 10, 2020 | clinicaltrials |
| NCT01611090 | A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 3 | 578 | Janssen Research & Development, LLCINDUSTRY | 21 | Mar 3, 2020 | clinicaltrials |
| NCT02801578 | A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 / Phase 3 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 27, 2020 | clinicaltrials |
| NCT00262782 | Fludarabine or Observation in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia | completed | Phase 3 | 877 | German CLL Study GroupOTHER | 2 | Feb 20, 2020 | clinicaltrials |
| NCT01118234 | Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) | completed | Phase 3 | 256 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 3 | Jan 9, 2020 | clinicaltrials |
| NCT01905943 | A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia | completed | Phase 3 | 979 | Hoffmann-La RocheINDUSTRY | 31 | Oct 28, 2019 | clinicaltrials |
| NCT01305200 | Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant | completed | Phase 3 | 226 | Children's Oncology GroupNETWORK | 3 | Sep 17, 2019 | clinicaltrials |
| NCT00910910 | Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)(ORIGIN) | completed | Phase 3 | 450 | CelgeneINDUSTRY | 27 | Jul 9, 2019 | clinicaltrials |
| NCT00262795 | Fludarabine or Chlorambucil as First-Line Therapy in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia | completed | Phase 3 | 206 | German CLL Study GroupOTHER | 2 | May 23, 2019 | clinicaltrials |
| NCT00275054 | Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia | completed | Phase 3 | 825 | German CLL Study GroupOTHER | 3 | May 23, 2019 | clinicaltrials |
| NCT00276848 | Fludarabine With or Without Cyclophosphamide in Treating Patients With Advanced Chronic Lymphocytic Leukemia | completed | Phase 3 | 375 | German CLL Study GroupOTHER | 2 | May 23, 2019 | clinicaltrials |
| NCT01539512 | A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) | completed | Phase 3 | 220 | Gilead SciencesINDUSTRY | 5 | May 14, 2019 | clinicaltrials |
| NCT01010061 | CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a) | completed | Phase 3 | 787 | Hoffmann-La RocheINDUSTRY | 26 | Sep 14, 2018 | clinicaltrials |
| NCT01998880 | CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b) | completed | Phase 3 | 787 | Hoffmann-La RocheINDUSTRY | 26 | Sep 14, 2018 | clinicaltrials |
| NCT02053610 | CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2) | completed | Phase 3 | 787 | Hoffmann-La RocheINDUSTRY | 26 | Sep 14, 2018 | clinicaltrials |
| NCT00718549 | A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL) | completed | Phase 3 | 128 | Hoffmann-La RocheINDUSTRY | 2 | Aug 20, 2018 | clinicaltrials |
| NCT01973387 | A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma | completed | Phase 3 | 160 | Janssen Research & Development, LLCINDUSTRY | 4 | Jul 24, 2018 | clinicaltrials |
| NCT00281892 | Fludarabine and Darbepoetin Alfa in Treating Older Patients With Chronic Lymphocytic Leukemia | completed | Phase 3 | 97 | German CLL Study GroupOTHER | 1 | May 11, 2018 | clinicaltrials |
Data updated 22 days agoSource updated Sep 1, 2026source: clinicaltrials